Current share price for CU6 : $2.140 0.04 (1.90%)+
Clarity Pharmaceuticals Ltd (CU6), an ASX-listed company, operates as a clinical stage radiopharmaceutical entity focused on treatment of serious diseases. The organisation develops TCTs based on the SAR Technology Platform for treatment of cancers.
| ASX Code | CU6 |
| Website | N/A |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 798 |
| CU6 Share Price | $2.140 |
| Day High | $2.320 |
| Day Low | $2.080 |
| Last Close | $2.100 |
| CU6 Share Price Movement | $0.04 ( 1.90% ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Clarity Pharmaceuticals Ltd (CU6) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | -$34.40 | 21.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | -$28.30 | 40.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$64.30 | -$20.10 | 30.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| Clarity Pharmaceuticals Ltd (CU6) | $677M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,547M | -0.7857 | 0.0743 | 1.2000 | 52.4280 | 48.8000 | 22.1818 | 0.00% | 0.00% | 0.00% |
| Name | Position | Start Date |
|---|---|---|
| Dr Alan John Taylor | Executive Chairman, Executive Director | 28 Nov 2013 |
| Ms Michelle Parker | Executive Director | 20 Sep 2024 |
| Ms Rosanne Elizabeth Robinson | Lead Independent Director, Non-Executive Director | 19 Oct 2010 |
| Dr Christopher Graham Roberts | Non-Executive Director | 24 Mar 2016 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 20 Apr 2026 | PARKER, Michelle | Sell | Direct Shares | 360,896 | $3.056 | $1,102,717.728 |
| 25 Nov 2025 | PARKER, Michelle | Issued | Options | 511,810 | $1.616 | $827,269.000 |
| 25 Nov 2025 | BIGGIN, Colin | Issued | Options | 487,439 | $1.616 | $787,875.000 |
See all changes in directors' interest & trades for Clarity Pharmaceuticals Ltd (CU6) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Mr David Green | Chief Financial Officer |
| Robert Cochrane Vickery | Chief Financial Officer,Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clarity Pharmaceuticals Ltd (CU6). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 24,366,695 (6.55%) | HSBC Custody Nominees Pty Ltd |
| 22,096,014 (5.94%) | Citicorp Nominees Pty Limited |
| 20,704,111 (5.57%) | J P Morgan Nominees Australia Pty Limited |
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 04 September 2026 | Report (Annual) |
| 27 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.